Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pain's Remoxy Skips Over Panel On Rocky Road To Market

Executive Summary

The FDA's decision not to hold an advisory committee meeting for Pain Therapeutics Inc.'s twice-before rejected Remoxy looks to bode well for the abuse-deterrent, extended-release oxycodone product – or at least, investors thought so.


Related Content

Pain Therapeutics Confident It Has US Approval Pathway Set For Remoxy ER
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
Abuse-Deterrent Opioids Effectiveness, Value To Get ICER Review
Pain rockets on positive results; plans Remoxy resubmission
Pfizer's surprise Remoxy withdrawal slashes Pain, Durect prices by half
Pfizer to give Remoxy another go after 2 FDA snubs; Pain soars
OxyContin wins 'abuse-deterrent' label, but FDA bans older generic forms
Pain Therapeutics, Durect take a beating over US FDA rejection of Remoxy
Remoxy receives FDA complete response letter


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts